Patient preferences for treatment attributes in Crohn’s disease (CD) or ulcerative colitis (UD) underscores the importance of personalized care and shared decision making in maximizing the benefits of available therapies for these conditions, according to data published in Inflammatory Bowel Disease. To explore patients’ preferences for treatment attributes of available IBD therapies, Gionata Fiorino, MD, PhD, and colleagues conducted a comprehensive online survey of 686 adults. Patients with both CD and UC prioritized the route of medication administration and the minimization of adverse events when considering treatment options. Results of the survey showed a strong preference for subcutaneous and oral treatments over IV, highlighting the significance of ease and safety in treatment decisions. The researchers also found that certain factors, including general well-being, energy levels, and the ability to perform daily activities were top priorities for improving QOL through treatment, underscoring the importance personalized care and shared decision making in maximizing the benefits of available therapies for CD and UC.
